Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2009; 134(25/26): 1309-1311
DOI: 10.1055/s-0029-1225280
DOI: 10.1055/s-0029-1225280
Klinischer Fortschritt | Commentary
© Georg Thieme Verlag KG Stuttgart · New York
Kardiologie 2009
Cardiology 2009Further Information
Publication History
Publication Date:
10 June 2009 (online)
Was ist neu?
-
Vorhofflimmern: Neue medikamentöse Therapiealternativen?
-
Herzinsuffizienz mit erhaltener Pumpfunktion: Behandlung bleibt empirisch.
-
Chronische systolische Herzinsuffizienz: Bewegung ist gut.
-
Kardiovaskuläre Ereignisse unter Clopidogrel: Genpolymorphismus identifiziert.
-
Statin-Therapie zur Reduktion kardiovaskulärer Ereignisse: Muss die Indikation geändert werden?
Literatur
- 1 Collet J P, Hulot J S, Pena A. et al . Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009; 373 309-317
- 2 Connolly S J, Pogue J, Hart R G. et al . Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med. 2009; 360 2066-2078
- 3 Disertori M, Latini R, Barlera S. et al . Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009; 360 1606-1617
- 4 Fellstrom B C, Jardine A G, Schmieder R E. et al . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360 1395-1407
- 5 Hohnloser S H, Crijns H J, van Eickels M. et al . Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360 668-678
- 6 Massie B M, Carson P E, McMurray J J. et al . Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359 2456-2467
- 7 Mega J L, Close S L, Wiviott S D. et al . Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360 354-362
- 8 O’Connor C M, Whellan D J, Lee K L. et al . Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009; 301 1439-1450
- 9 Ridker P M, Danielson E, Fonseca F A. et al . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359 2195-2207
- 10 Ridker P M, Danielson E, Fonseca F A. et al . Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009; 373 1175-1182
- 11 Roy D, Talajic M, Nattel S. et al . Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358 2667-2677
- 12 Simon T, Verstuyft C, Mary-Krause M. et al . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360 363-375
- 13 Tavazzi L, Maggioni A P, Marchioli R. et al . Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372 1231-1239
Prof. Dr. med. Uta C. Hoppe
Klinik III für Innere Medizin, Universität
zu Köln
Kerpener Straße 62
50937
Köln
Phone: 0221/47832396
Fax: 0221/47832397
Email: Uta.Hoppe@uni-koeln.de